Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
about
New Antituberculosis Drugs: From Clinical Trial to Programmatic UseNew agents for the treatment of drug-resistant Mycobacterium tuberculosisCarbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic ReviewEmerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Extensively drug-resistant tuberculosis: epidemiology and managementWHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysisVaccines for TB: Lessons from the Past Translating into Future PotentialsNew developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanidNew insights into TB physiology suggest untapped therapeutic opportunitiesNew anti-tuberculosis drugs and regimens: 2015 updateCombined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.Binding and processing of β-lactam antibiotics by the transpeptidase LdtMt2 from Mycobacterium tuberculosis.Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic.Non-classical transpeptidases yield insight into new antibacterialsGlobal control of tuberculosis: from extensively drug-resistant to untreatable tuberculosisFatal anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder in tuberculosisSynthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to β-lactamsHigh rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, IndiaThe path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.Tuberculosis treatment and drug regimens.Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis InfectionPerspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.The multidrug-resistant tuberculosis threat: old problems and new solutionsIdentification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens.In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases.Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis.Drug-Resistant Tuberculosis: Challenges and Progress.Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis.Emerging drugs and alternative possibilities in the treatment of tuberculosis.Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.WHO strategies for the programmatic management of drug-resistant tuberculosis.An Update on Repurposed Medications for the Treatment of Drug-Resistant Tuberculosis.Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives.News on therapeutic management of MDR-tuberculosis: a literature review.Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method.
P2860
Q26741138-D68B2B1F-53AF-4864-A7D4-149C54D95172Q26751463-F39EEC9D-A2F3-407D-8AEE-93B49A883F5FQ26764847-B5FA4216-E8C5-49F5-A9AA-2E412FB7AE62Q26771997-2183AFFB-1CCF-4D50-9B0A-685C19903EF3Q26830094-36B99490-7B2B-4B1E-9F90-D4DE0BBFDFE0Q26852253-4A792C0E-37F8-4D6F-8AB1-263B632B69F9Q26996673-81A62AD6-21A0-433C-85BC-8EC7EF516A1BQ27003210-656F94D0-7F31-4CFE-934B-D300B5399553Q28388477-988B436D-FBC1-4A72-97BE-04D582BCE4A5Q28596775-BAEC3C9B-C5D4-4089-A5D4-9516207D29EDQ30236048-CB094A7E-BF22-42C1-BA6E-24541D0B0083Q30397294-6D52CE86-0DC8-4A45-BA96-9D42458673D4Q30573127-4E3F2BDD-10A4-447B-BF58-C1895AA7A2BCQ30620897-B0B44DBF-DB4F-4148-86D1-437AB41F83ABQ33814192-A459FEAF-7EAB-48EF-A337-0BC7318E382BQ33926262-EE09897C-DBA0-41FC-B3E2-F0486A5E22A5Q34150992-BB2BF419-D56F-4372-AC50-3A31110D5768Q34229876-FC0277DB-E4D8-4FE3-A275-412596F16107Q35032535-0C6B3586-65D7-46B1-8B95-8220AF1EC606Q35125060-B69B5FA8-A3C7-47E9-8FE2-16FC9A8166B3Q35663866-ECAEB863-61E5-4B21-B6C9-4C0503447FAEQ35860128-93829EE4-D52C-429C-BEB0-9102577D1B61Q36094215-E0318A54-EB77-4DA6-A769-7B36E77453DAQ36138237-210FEE40-775C-4FAB-8C79-E61E47EB35C9Q36355735-C384C72D-1ABD-4596-9D88-8247DBF397CAQ36438910-19EAF727-50E4-47E5-8792-CC2AF8D0CC87Q36490639-193ADBA4-DFB4-4F57-BD86-F570B78626B7Q36888124-60560F5B-0E4D-4CC3-8A10-70AF12CEED0AQ36924283-AA3C30E7-3BC3-479A-9841-FD7131B714C5Q38232824-4A957E87-FAAE-485C-8922-048BD03A4954Q38724073-0FAD3186-A30B-43E1-A5B2-DF01EA82DE7CQ38763608-77F2F940-7CC0-4AF3-AD57-A7DE6DE7AC7BQ38777085-DF6F1E86-E861-4AEE-A442-9DD081ED4748Q38856343-D4BA9448-4F3A-4876-A87B-DC434424DD2FQ38885365-049A20E9-1BA5-4C72-B25A-C1DD3ACEAF40Q39038482-064E2D2C-A3B9-4E4D-8F1E-1B5A19A4453CQ39398924-C38C5C0B-F764-45FE-8FDC-4C856BA64D31Q40080040-54B4FC90-7CAC-49C9-B70F-8F3E6A8A1A3FQ40675039-FFB42453-FEBC-4A66-B743-FD1FD15E376AQ41075817-AAB315D5-EB2C-4593-A660-878A2E153398
P2860
Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.
@en
Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.
@nl
type
label
Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.
@en
Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.
@nl
prefLabel
Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.
@en
Efficacy and safety of meropen ...... the treatment of MDR-/XDR-TB.
@nl
P2093
P50
P1476
Efficacy and safety of meropen ...... n the treatment of MDR-/XDR-TB
@en
P2093
Jan Wilem Alffenaar
Lia D'Ambrosio
Mathieu S Bolhuis
Piero Viggiani
Richard van Altena
Saverio De Lorenzo
P304
P356
10.1183/09031936.00124312
P577
2012-09-20T00:00:00Z